Amphastar Pharma Cash Flow - Annual (NASDAQ:AMPH)

Add to My Stocks
$15.77 $0.33 (2.05%) AMPH stock closing price Jun 22, 2018 (Closing)

The Amphastar Pharma cash flow statement is one of the important reports considered by investors doing a fundamental analysis of the company. Financials statements like the Amphastar Pharma income statement and Amphastar Pharma balance sheet show that the company has profits and debt, while the cash flow statement provides details of cash flow movments. The cash flow statement is essetial while conducting the Amphastar Pharma cash flow analysis and can be used to measure the operating performance of Amphastar Pharma compared to various industry peers like BTCA stock and ASMB stock. The cash from operating activities for Amphastar Pharma is $ 2017, which saw an increase from previous year.

View details of Amphastar Pharma cash flows for latest & last 10 financial years
show more
View Previous Years
View Next Years
Fiscal year is Jan - Dec2017201620152014201320122011
Net Income Cash Flow
Depreciation Depletion Amortization Cash-Flow15.43M14.56M13.25M14.44M13.07M11.49M11.15M
Net Increase (Decrease) in Assets Liabilities---5.13M15.61M-3.23M-49.64M27.57M
Cash From (used in) Discontinued Operations-------
Other Adjustments Net18.68M13.16M5.35M1.68M9.33M18.4M-27.38M
Net Cash from (used by) Operating Activities
Increase (Decrease) in Prop Plant And Equipment-35.09M-21.38M-15.99M-20.49M-18.3M-23.66M-10.67M
Acquisition Disposition of Subsidiaires--12.46M--18.35M---
Increase (Decrease) in Investments-1.99M-0.52M-----
Other Cash Inflow (Outflow) from Investment Activities-1.66M-5.13M-0.92M-0.92M-0.5M-2.26M-0.04M
Net Cash from (used by) Investment Activities
Issuance (Purchase) of Equity Shares-16.98M10.73M4.33M37.85M-0.14M-0.47M-1.69M
Issuance (Repayment) of Debt Securities9.27M-4.45M-2.2M3.28M-7.15M23.83M-5.9M
Increase (Decrease) in Bank & Other Borrowings----5.99M---
Payment of Dividends & Other Cash Distributions-------
Other Cash from (used by) Financing Activities----3.02M-2.07M-0.12M-0.98M
Net Cash from (used by) Financing Activities
Effect of Exchange Rate Changes on Cash--2.25M----
Net Change in Cash & Cash Equivalents
Cash & Equivalents at Beginning of Year72.35M66.07M67.82M53.58M50.21M53.73M53.75M
Cash & Equivalents at Year End65.59M72.35M66.07M67.82M53.58M50.21M53.73M
All figures in USD. M: Millions of USD, B: Billions of USD.
View Previous Years
View Next Years

Amphastar Pharma stock price history provides insight into historical stock price fluctuations, and Amphastar Pharma stock comparison chart enables peer comparison. Some of the key terms used in the statement of cash flows are:

  • Amphastar Pharma has cash of $65.59M on hand. A healthy amount of cash on hand is necessary for any company. Cash has an opportunity cost associated with it, and too much cash in bank may mean that the firm has no or limited growth plans. Hence its important to track the Net Change in Cash and Cash Equivalents along with the Amphastar Pharma stock price.
  • Cash Flow from operating activities: Operating activities include the core business activities. This line item refers to the cash generated from the same and stood at a positive value of $39.2M for AMPH.
  • Cash Flow from investment activities: Amphastar Pharma used $-38.75M cash due to investment activities. It includes the use of cash outside of normal day to day activities like buying fixed assets, plant and machinery etc.
  • Cash Flow from financing activities: The cash inflow/outflow from financing activities was $-7.71M for Amphastar Pharma. The money accounted for under this head comes from external sources which includes lenders, investors and shareholders. Positive cash flow is generated when the company gets cash because of issuance of stocks or bonds. Similarly negative cash flow is generated when shares are repurchased, dividend payments are made, and loans or interest on loans are paid back.

Key Financial Ratios For Amphastar Pharma Cash Flow

Annual Cash Flow Statements For Amphastar Pharmaceuticals Inc Peers

Ventrus Biosciences cash flow, Halozyme Therapeutics cash flow, Sanofi cash flow, Teligent cash flow